Ramos CA,Dotti G.Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy[J].Expert Opin Biol Ther,2011,11(7):855-873.
[2]
Kochenderfer JN,Wilson WH,Janik JE,et al.Eradication of B-lineage cells and regression of lymphoma in apatient treated with autologous T cells genetically engineered to recognize CD19[J].Blood,2010,116(20):4 099-4 102.
[3]
Jahn L,Hagedoorn RS,van der Steen DM,et al.A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer[J].Oncotarget,2016,7(44):715 36-71 547.
[4]
Puig M,Mihalik K,Yu MY,et al.Sensitivity and reproducibility of HCV quantitation in chimpanzee sera using TaqMan real-time PCR assay[J].J Virol Methods,2002,105(2):253-263.
[5]
Ataca P,Arslan O.Chimeric Antigen Receptor T Cell Therapy in Hematology[J].Turk J Haematol,2015,32(4):285-294.
[6]
Chicaybam L,Sodre AL,Bonamino M.Chimeric antigen receptors in cancer immuno-gene therapy:current status and future directions[J].Int Rev Immunol,2011,30(5-6):294-311.
[7]
Figueroa JA,Reidy A,Mirandola L,et al.Chimeric antigen receptor engineering:a right step in the evolution of adoptive cellular immunotherapy[J].Int Rev Immunol,2015,34(2):154-187.
[8]
韩为东,魏建树,罗灿.CART细胞在血液系统恶性肿瘤疾病中的临床转化研究[J].临床血液学杂志,2016,29(4):547-552.Han WD,Wei JS,Luo C.Clinical translational research of chimeric antigen receptor modified T cells in hematological malignancies[J].J Clin Hematol(China),2016,29(4):547-552.
[9]
Zhang Y,Zhang W,Dai H,et al.An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19chimeric antigen receptor T(CAR-T)cells[J].Sci China Life Sci,2016,59(4):379-385.
[10]
James SE,Greenberg PD,Jensen MC,et al.Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane[J].J Immunol,2008,180(10):7 028-7 038.
[11]
Gargett T,Brown MP.Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2[J].Cytotherapy,2015,17(4):487-495.
[12]
Brentjens RJ,Riviere I,Park JH,et al.Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias[J].Blood,2011,118(18):4 817-4 828.
[13]
Zhu Y,Tan Y,Ou R,et al.Anti-CD19chimeric antigen receptor-modified T cells for B-cell malignancies:a systematic review of efficacy and safety in clinical trials[J].Eur J Haematol,2016,96(4):389-396.
[14]
Jensen MC,Popplewell L,Cooper LJ,et al.Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans[J].Biol Blood Marrow Transplant,2010,16(9):1 245-1 256.
[15]
Maude SL,Frey N,Shaw PA,et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med,2014,371(16):1 507-1 517.
[16]
Porter DL,Levine BL,Kalos M,et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J].N Engl J Med,2011,365(8):725-733.
